Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Results of the CheckMate 039 Trial
2016 ASH Annual Meeting & ExpositionStephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses phase I study findings on nivolumab in combination with ipilimumab for relapsed or refractory disease (Abstract 183).
Related Videos
Smita Bhatia, MD, MPH, and Jessica Wu, BA, on CML: A Report From the Bone Marrow Transplant Survivor Study
Smita Bhatia, MD, MPH, and Jessica Wu, BA, both of the University of Alabama at Birmingham, discuss long-term morbidity and mortality experienced by chronic myeloid l...
Umberto Vitolo, MD, and Sagar Lonial, MD, on DLBCL: Final Results From the GOYA Trial
Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab o...
Andrew D. Zelenetz, MD, on CLL: Emerging Treatments
Andrew D. Zelenetz, MD, of the Memorial Sloan Kettering Cancer Center, discusses novel treatments for chronic lymphocytic leukemia, touching specifically on the Gilead 115 trial.
Jeffrey E. Lancet, MD, on AML: Subgroup Analysis of a Phase III Trial
Jeffrey E. Lancet, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses study findings on survival following allogeneic hematopoietic cell transplantation in olde...
Joshua Brody, MD, on Lymphoid Malignancies: Immunotherapy Update
Joshua Brody, MD, of the Icahn School of Medicine at Mount Sinai, summarizes important data on passive and active immunotherapy (Abstracts 1213, 1214, 1215, 1216, 1217, 1218).
